Curriculum Vitae M.C. Fantini



Personal information and contacts:

Name:	Massimo Claudio
Surname:	Fantini
Age	48
Place and date of birth	Johannesburg (South Africa) July the 7th 1976
Work address	University of Cagliari Dep. of Medical Science and Public Health. Cittadella Universitaria di Monserrato - Asse Didattico I SS 554 bivio Sestu - 09042 Monserrato (CA), Italy
Phone	+39(070)6754621
Fax	
Mobile	**********
Email:	massimoc.fantini@unica.it
PEC:	massimo.fantini@pec.it

Current Position:

Professor of Gastroenterology at the University of Cagliari, Dep. of Medical Science and Public Health.

Head of the Gastroenterology Unit at the Azienda Ospedaliero-Universitaria (AOU) di Cagliari, Italy.

Academic Background:

2001 2001 Undergraduate scholarship at the University of Kiel (Germany), Christian Albrecht, MUCOSA laboratories (Prof.Dr. Stefan Schreiber).

2002 Degree in Medicine and Surgery at the University of Rome “Tor Vergata”, Italy. Final mark 110/110 cum laude Dissertation on ”Expression of NOD2 in epithelial cell lines HT-29 and HeLa”

2003 Medical license: Ordine provinciale di Roma dei Medici Chirurghi e degli Odontoiatri (M52402)

Postgraduate positions:

2003-2005 Research fellow at the University of Mainz (Germany), Johannes Gutenberg, at the Laboratories of Mucosal Immunology (Prof. Dr. Markus F. Neurath).

2005	PhD in "Experimental physiopathology: Mucosal Immunology" at the University of Rome "Tor Vergata", Department of Internal Medicine, Division of Gastroenterology (Coordinator Prof. Dr. Francesco Pallone). Dissertation on "Role of TGF-beta in colitis and colitis associated colorectal cancer"
2006-2009	Post-graduate school of Gastroenterology.
2006-2009	PostDoc position at the University "Tor Vergata", Rome, Italy (Prof. Dr. Monteleone)
2009-2013	Professorship at the University of Rome "Tor Vergata", research program "Rientro dei cervelli".
2013-2014	Assistant Professor at the University of Rome "Tor Vergata", Rome, Italy
2014-2019	Associate Professor of Gastroenterology at the University of Rome "Tor Vergata", Italy
2019-2024	Associate Professor of Gastroenterology and head of the Inflammatory Bowel Unit at the University of Cagliari, Italy.
2021-present	Head of the Gastroenterology Unit at Azienda Ospedaliero-Universitaria (AOU) di Cagliari, Italy.
2024-present	Professor of Gastroenterology at the University of Cagliari, Italy.

Scientific Activity: publications

The products of my research activity have been published in:

New England Journal of Medicine

Nature Clinical Practice in Gastroenterology and Hepatology

Molecular Cancer Therapy

Molecular Therapy

Journal of Experimental Medicine

Carcinogenesis

Cancer Research

World Journal of Gastroenterology

Blood

Immunity

Gastroenterology

Gut

Alimentary Pharmacology & Therapeutics

The Journal of Immunology

Journal of Biological Chemistry

Cell Cycle

Biology of Reproduction

European Journal of Immunology

Infection Immunology

Inflammatory Bowel Disease,

Current Drug Targets

Nature Protocols

Expert Review in Anticancer Therapy.

Digestive and Liver Disease

Publication metrics (source SCOPUS):

Since 1999 to present.

Total publications: 115

Totale citations: 9447*

h-Index: 47*

*Self-citation excluded

Awards and granted projects:

2001 SIGE (Società Italiana di Gastroenterologia) research prize.

2005 30.000€ for one year granted by the "Forschunggörderungsprogramm MAIFOR 2005" for the project "Characterization and modulation of tumor induced regulatory T cells in melanoma and colorectal cancer". Role: **Responsible of the fund and Principal Investigator**.

2008 *Rising Star in Gastroenterology* award, nominated by the ASNEMGE.

2009 150.000€ MFAG AIRC grant (Cod. 9363) for studying the "Role of Smad7 in the immune-modulation of inflammation-related colorectal cancer". Role: **Responsible of the fund and Principal Investigator**.

2011 "Fondazione Aldo Torsoli per le le Malattie dell'Apparato digerente del Fegato e del Pancreas" award.

2012 900.000€ FIRB (Fondo per gli Investimenti della Ricerca di Base) grant for studying "New molecular and cellular mechanisms involved in colitis-associated colorectal cancer: implications for innovative therapeutic approaches". Role: **Coordinator of the fund and Principal Investigator.**

2012 IG AIRC grant (Cod. 13304)for the study "T cell plasticity in colitis-associated colorectal cancer", three years grant 54.000€ funded for the first year. Role: **Responsible of the fund and Principal Investigator.**

2018 Investigator Initiated Study (IIS) "Immuno-profiling of patients affected by Crohn's disease undergoing anti-(IL12/IL23) p40 Ustekinumab. PROfiling USTekinumab (PROUST) study" 75.000€ grated by Jannsen-Cilag. Role: **Responsible of the fund and Principal Investigator.**

2018 ASPIRE (Pfizer) research grant. Title "(A)nalysis of immunological (VA)riables in ex vivo (T)ofacitinib-treated human biopsies from (A)ctive ulcerative colitis patients to predict clinical (R)esponse (the AVATAR study)" 200.000€ granted. Role: **Responsible of the fund and Principal Investigator.**

2022 PNRR-MAD-2022-12376852 research grant "Cell-free DNA as biomarker of intestinal inflammation in Inflammatory Bowel Disease" 432.998,00 € granted. **Responsible of the fund and Principal Investigator.**

2023 PRIN2022 research grant. “Functional CHaracterization of Adenoma-Specific Microbial ecosystem and metabolomE (the CHAShMirE study)”. 279,859.83€ granted. **Coordinator of the fund and Principal Investigator.**

2023 Fondazione di Sardegna (FdS) research grant program, “Xanthine Oxidase as a new therapeutic target in Inflammatory Bowel Disease patients” F73C23001660007, 55.309,05 € granted. **Responsible of the fund and Principal Investigator.**

Scientific activity:

Clinical research:

Last GCP certificate ICH GOOD CLINICAL PRACTICE E6 (R2), The Global Helath Network, June the 8th 2021

Research and development of new drugs for the therapy of Inflammatory Bowel Disease (IBD).

1) Participation as sub-investigator in the phase 1 trial for the assessment of safety, tolerability and pharmacokinetic of the Smad7 antisense oligonucleotide (**GED301 Mongersen**) in Crohn's disease.
2) Participation as sub-investigator in the phase 2b randomized controlled trial for the assessment of efficacy and safety of **GED301 Mongersen** in Crohn's disease. EudraCT number: 2011-002640-27.
3) Participation as sub-investigator in the open-labeled phase 1/2a to evaluate safety, efficacy and pharmacokinetic of **Niclosamide** enemas in ulcerative colitis. EudraCT numebr: 2017-000319-18
4) Participation as sub-investigator in the phase 2b/3 trial SELECTION GS-US 418 3898 (Gilead), to evaluate the efficacy of **Filgotinib** in inducing clinical remission in UC, EudraCT 2016-001392-78
5) Participation as sub-investigator in the phase 2b/3 trial M14-234 ABT 494 (Abbvie), to evaluate the efficacy of **Upadacitinib** for the induction clinical remission in UC, EudraCT 2016-000641-31
6) Participation as sub-investigator in the phase 3 trial M14-533 ABT 494 (Abbvie), to evaluate the efficacy of **Upadacitinib** in UC LT extension, EudraCT 2016-000674-38
7) Participation as sub-investigator in the phase 2b/3 trial M14-431 ABT 494 (Abbvie), to evaluate the efficacy of **Upadacitinib** for the induction of clinical remission in CD, EudraCT 2017-001225-41
8) Participation as sub-investigator in the phase 2b/3 trial M14-431 ABT 494 (Abbvie), to evaluate the efficacy of **Upadacitinib** for the induction of clinical remission in CD, EudraCT 2017-001240-35
9) Participation as sub-investigator in the phase 3 trial M14-430 ABT 494 (Abbvie), to evaluate the efficacy of **Upadacitinib** in CD LT extension, EudraCT 2017-001225-41
10) Participation as sub-investigator in the phase 3 trial M15-991 Risankizumab (Abbvie), to evaluate the efficacy of **Risankizumab** for the induction of clinical remission in CD, EUDRACT 2016-003190-17
11) Participation as sub-investigator in the phase 3 trial M16-006 Risankizumab (Abbvie) to evaluate the efficacy of **Risankizumab** for the induction of clinical remission in CD, EudraCT 2016-003123-32
12) Participation as sub-investigator in the phase 3 trial M16-000 Risankizumab (Abbvie) to evaluate the efficacy of **Risankizumab** for the maintenance of clinical remission in CD, EudraCT 2016-003191-50

13) Participation as sub-investigator in the phase 3 trial M16-067 Risankizumab (Abbvie) to evaluate the efficacy of **Risankizumab** for the induction of clinical remission in UC, EudraCT 2016-004677-40
14) Participation as sub-investigator in the phase 3 trial M16-065 Risankizumab (Abbvie) to evaluate the efficacy of **Risankizumab** for the induction of clinical remission in UC.
15) Participation as sub-investigator in the phase 3 trial M16-066 Risankizumab (Abbvie) to evaluate the efficacy of **Risankizumab** for the maintenance of clinical remission in UC. EudraCT 2016-004676-22.
16) Participation as sub-investigator in the phase 3 trial CC-10004-UC-001 (Celgene) to evaluate the efficacy of **Apremilast** for the induction of clinical remission in UC, EudraCT 2014-002981-64
17) Participation as Principal Investigator in the phase 3 trial. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-
18) Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients
19) with Moderately to Severely Active Crohn's Disease A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of **Mirikizumab** in Patients with Moderately to Severely Active Crohn's Disease EudraCT number: 2018-004614-18
20) Participation as Principal Investigator in the phase 2/3 trial. A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of **Guselkumab** in Participants with Moderately to Severely Active Crohn's Disease. EudraCT number: 2017-002195-13
21) Participation as Principal Investigator in the phase 2 trial. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of **BMS-986165** in Subjects with Moderate to Severe Crohn's Disease. EudraCT number 2017-001976-48
22) Participation as Principal Investigator in the phase 3 trial. A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a **Novel Hydrocortisone Acetate 90 mg** Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum. EudraCT number 2019-003596-19

Basic science research:

1) Mechanisms of mucosal immuno-regulation in human inflammatory bowel disease:
    a. Study of TGF-beta in the immuno-regulation of the gut mucosal immune system.
    b. Description of the role played by TGF-beta in the peripheral induction of CD4+CD25+FoxP3+ regulatory T cells from a population of naive cells.
    c. Characterization of the suppressive effect of TGF-beta induced regulatory cells in Th1 mediated colitis.
    d. Study of the *in vivo* relevance of the peripheral induction of regulatory cells by TGF-beta.

e. Study of the mechanisms modulating the induction and regulatory function of TGF-beta induced regulatory cells.
f. Identification of TGF-beta dependent counter regulatory systems different from the induction of regulatory cells.

2) Regulation of the mucosal immune response by colorectal cancer
   a. Study of the TGF-beta dependent mechanisms involved in the immune response evoked by primary and metastatic colorectal cancer.
   c. Description of the role of *IL-6 transignalling* in colorectal cancer
   d. Study of the role played by TGF-beta induced regulatory cells in the phenomenon of immunosurveillance evasion.
   e. Study of the tumor derived TGF-beta effects in the modulation of the immune system during the process of metastatization.
   f. Study of the role of T cell-specific Smad7 expression in colitis-associated colorectal cancer.

3) Functional and phenotypic plasticity of regulatory T cells:
   a. Study of the role played by RORgamma-t-expressing regulatory T cells in colitis-associated colorectal cancer.
   b. Study of the role played by Tbet-expressing regulatory T cells in models of acute colitis.

Positions in Scientific Societies and Memberships:

2022-present General Secretary of the Italian Group for thr study of Inflammatoy Bowel Disease (IG-IBD)

2022-2024 Member of the steering committee of the Italian Group for thr study of Inflammatoy Bowel Disease (IG-IBD)

2017-2018 Federazione Italiana delle Società scientifiche per le Malattie Digestive (FISMAD): member of the steering committee.

2015-2018 Italian Society of Gastroenterology and Endoscopy (SIGE): member steering committee.

Italian Group for Intestinal Bowel Disease (IG-IBD): member of scientific board.

European Crohn's and Colitis Organization (ECCO): member.

United European Gastroenterology (UEG): National Society Forum member.

Publications:

1. Spatiotemporal patterns of expression of neurotrophins and neurotrophin receptors in mice suggest functional roles in testicular and epididymal morphogenesis. Russo MA, Giustizieri ML, Favale A, **Fantini MC**, Campagnolo L, Konda D, Germano F, Farini D, Manna C, Siracusa G. Biol Reprod. 1999 Oct;61(4):1123-32
2. Review article: maintenance treatment of Crohn's disease. Biancone L, Tosti C, Fina D, **Fantini M**, De Nigris F, Geremia A, Pallone F. Aliment Pharmacol Ther. 2003 Jun;17 Suppl 2:31-7.
3. Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease. Biancone L, Tosti C, De Nigris F, **Fantini M**, Pallone F. Gastroenterology. 2003 Aug;125(2):637-8.
4. Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum. Biancone L, **Fantini M**, Tosti C, Bozzi R, Vavassori P, Pallone F. Eur J Gastroenterol Hepatol. 2003 Mar;15(3):261-6.
5. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Rosenstiel P, **Fantini M**, Bräutigam K, Kühbacher T, Waetzig GH, Seegert D, Schreiber S. Gastroenterology. 2003 Apr;124(4):1001-9.
6. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Becker C, **Fantini MC**, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF. Immunity. 2004 Oct;21(4):491-501.
7. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. **Fantini MC**, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. J Immunol. 2004 May 1;172(9):5149-53.
8. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. Monteleone G, Mann J, Monteleone I, Vavassori P, Bremner R, **Fantini M**, Del Vecchio Blanco G, Tersigni R, Alessandroni L, Mann D, Pallone F, MacDonald TT. J Biol Chem. 2004 Feb 6;279(6):3925-32. Epub 2003 Nov 4.
9. IL-6 signaling promotes tumor growth in colorectal cancer. Becker C, **Fantini MC**, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF. Cell Cycle. 2005 Feb;4(2):217-20. Epub 2005 Feb 3.
10. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Becker C, **Fantini MC**, Wirtz S, Nikolaev A, Kiesslich R, Lehr HA, Galle PR, Neurath MF. Gut. 2005 Jul;54(7):950-4.
11. Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy. **Fantini MC**, Becker C, Neurath MF. Expert Rev Anticancer Ther. 2005 Aug;5(4):681-94.
12. EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation. Wirtz S, Becker C, **Fantini MC**, Nieuwenhuis EE, Tubbe I, Galle PR, Schild HJ, Birkenbach M, Blumberg RS, Neurath MF. J Immunol. 2005 Mar 1;174(5):2814-24.

13. TGF-beta as a T cell regulator in colitis and colon cancer. Becker C, **Fantini MC**, Neurath MF. Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):97-106. Epub 2005 Nov 18.
14. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. Becker C, Dornhoff H, Neufert C, **Fantini MC**, Wirtz S, Huebner S, Nikolaev A, Lehr HA, Murphy AJ, Valenzuela DM, Yancopoulos GD, Galle PR, Karow M, Neurath MF. J Immunol. 2006 Sep 1;177(5):2760-4.
15. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. **Fantini MC**, Becker C, Tubbe I, Nikolaev A, Lehr HA, Galle P, Neurath MF. Gut. 2006 May;55(5):671-80. Epub 2005 Sep 14.
16. Drug insight: novel small molecules and drugs for immunosuppression. **Fantini MC**, Becker C, Kiesslich R, Neurath MF. Nat Clin Pract Gastroenterol Hepatol. 2006 Nov;3(11):633-44.
17. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C, **Fantini MC**, Caprioli F, Tersigni R, Alessandroni L, MacDonald TT, Pallone F. Gut. 2006 Dec;55(12):1774-80. Epub 2006 May 8.
18. In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. **Fantini MC**, Dominitzki S, Rizzo A, Neurath MF, Becker C. Nat Protoc. 2007;2(7):1789-94.
19. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Neufert C, Becker C, Wirtz S, **Fantini MC**, Weigmann B, Galle PR, Neurath MF. Eur J Immunol. 2007 Jul;37(7):1809-16.
20. Role of interleukin-21 in inflammation and allergy. Fina D, **Fantini MC**, Pallone F, Monteleone G. Inflamm Allergy Drug Targets. 2007 Mar;6(1):63-8.
21. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. **Fantini M**C, Rizzo A, Fina D, Caruso R, Becker C, Neurath MF, Macdonald TT, Pallone F, Monteleone G. Eur J Immunol. 2007 Nov;37(11):3155-63.
22. New players in the cytokine orchestra of inflammatory bowel disease. **Fantini MC**, Monteleone G, Macdonald TT. Inflamm Bowel Dis. 2007 Nov;13(11):1419-23.
23. In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. **Fantini MC**, Dominitzki S, Rizzo A, Neurath MF, Becker C. Nat Protoc. 2007;2(7):1789-94.
24. Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. Peluso I, Fina D, Caruso R, Stolfi C, Caprioli F, **Fantini MC**, Caspani G, Grossi E, Di Iorio L, Paone FM, Pallone F, Monteleone G. Infect Immun. 2007 Apr;75(4):1730-7. Epub 2007 Jan 22.
25. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. Peluso I, **Fantini MC**, Fina D, Caruso R, Boirivant M, MacDonald TT, Pallone F, Monteleone G. J Immunol. 2007 Jan 15;178(2):732-9.
26. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Caruso R, Fina D, Peluso I, Stolfi C, **Fantini MC**, Gioia V, Caprioli F, Del Vecchio Blanco G, Paoluzi OA, Macdonald TT, Pallone F, Monteleone G. Gastroenterology. 2007 Jan;132(1):166-75. Epub 2006 Oct 1.
27. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. Caruso R, Fina D, Peluso I, **Fantini MC**, Tosti C, Del Vecchio Blanco G, Paoluzi OA, Caprioli F, Andrei F, Stolfi C, Romano M, Ricci V, MacDonald TT, Pallone F, Monteleone G. J Immunol. 2007 May 1;178(9):5957-65.

28. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. Dominitzki S, **Fantini MC**, Neufert C, Nikolaev A, Galle PR, Scheller J, Monteleone G, Rose-John S, Neurath MF, Becker C. J Immunol. 2007 Aug 15;179(4):2041-5.
29. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Stolfi C, Fina D, Caruso R, Caprioli F, **Fantini MC**, Rizzo A, Sarra M, Pallone F, Monteleone G. Carcinogenesis. 2008 Jun;29(6):1258-66. doi: 10.1093/carcin/bgn122. Epub 2008 May 20.
30. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, **Fantini MC**, Rizzo A, Pallone F, Monteleone G. Biochem Pharmacol. 2008 Feb 1;75(3):668-76. Epub 2007 Sep 29.
31. Regulation of gut inflammation and th17 cell response by interleukin-21. Fina D, Sarra M, **Fantini MC**, Rizzo A, Caruso R, Caprioli F, Stolfi C, Cardolini I, Dottori M, Boirivant M, Pallone F, Macdonald TT, Monteleone G. Gastroenterology. 2008 Apr;134(4):1038-48. doi: 10.1053/j.gastro.2008.01.041. Epub 2008 Jan 17.
32. Cytokines: from gut inflammation to colorectal cancer. Fantini MC, Pallone F. Curr Drug Targets. 2008 May;9(5):375-80.
33. IL-21 comes of age as a regulator of effector T cells in the gut. **Fantini MC**, Monteleone G, MacDonald TT. Mucosal Immunol. 2008 Mar;1(2):110-5. doi: 10.1038/mi.2007.17. Epub 2008 Jan 23.
34. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Caruso R, Fina D, Paoluzi OA, Del Vecchio Blanco G, Stolfi C, Rizzo A, Caprioli F, Sarra M, Andrei F, **Fantini MC**, MacDonald TT, Pallone F, Monteleone G. Eur J Immunol. 2008 Feb;38(2):470-8. doi: 10.1002/eji.200737635.
35. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Vetrano S, Rescigno M, Cera MR, Correale C, Rumio C, Doni A, **Fantini MC**, Sturm A, Borroni E, Repici A, Locati M, Malesci A, Dejana E, Danese S. Gastroenterology. 2008 Jul;135(1):173-84. doi: 10.1053/j.gastro.2008.04.002. Epub 2008 Apr 11.
36. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. **Fantini MC**, Rizzo A, Fina D, Caruso R, Sarra M, Stolfi C, Becker C, Macdonald TT, Pallone F, Neurath MF, Monteleone G. Gastroenterology. 2009 Apr;136(4):1308-16, e1-3. doi: 10.1053/j.gastro.2008.12.053. Epub 2008 Dec 27.
37. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. **Fantini MC**, Pallone F, Monteleone G. World J Gastroenterol. 2009 May 28;15(20):2472-8.
38. Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Caruso R, Stolfi C, Sarra M, Rizzo A, **Fantini MC**, Pallone F, MacDonald TT, Monteleone G. Blood. 2009 Apr 9;113(15):3512-9. doi: 10.1182/blood-2008-08-172767. Epub 2009 Jan 7.
39. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Caruso R, Sarra M, Stolfi C, Rizzo A, Fina D, **Fantini MC**, Pallone F, MacDonald TT, Monteleone G. Gastroenterology. 2009 Jun;136(7):2270-9. doi: 10.1053/j.gastro.2009.02.049.

40. The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Vetrano S, Borroni EM, Sarukhan A, Savino B, Bonecchi R, Correale C, Arena V, **Fantini MC**, Roncalli M, Malesci A, Mantovani A, Locati M, Danese S. Gut. 2010 Feb;59(2):197-206. doi: 10.1136/gut.2009.183772. Epub 2009 Oct 20.
41. Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine. Stolfi C, Sarra M, Caruso R, **Fantini MC**, Fina D, Pellegrini R, Palmieri G, Macdonald TT, Pallone F, Monteleone G. Gastroenterology. 2010 Jan;138(1):221-30. doi: 10.1053/j.gastro.2009.08.062. Epub 2009 Sep 6.
42. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Sarra M, Monteleone I, Stolfi C, **Fantini MC**, Sileri P, Sica G, Tersigni R, Macdonald TT, Pallone F, Monteleone G. Inflamm Bowel Dis. 2010 Aug;16(8):1332-9. doi: 10.1002/ibd.21238.
43. Intestinal inflammation and colorectal cancer: a double-edged sword? Rizzo A, Pallone F, Monteleone G, **Fantini MC**. World J Gastroenterol. 2011 Jul 14;17(26):3092-100. doi: 10.3748/wjg.v17.i26.3092.
44. Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Rizzo A, Monteleone I, Fina D, Stolfi C, Caruso R, **Fantini MC**, Franzè E, Schwendener R, Pallone F, Monteleone G. Inflamm Bowel Dis. 2012 Mar;18(3):449-59. doi: 10.1002/ibd.21799. Epub 2011 Jun 17.
45. Smad7 expression in T cells prevents colitis-associated cancer. Rizzo A, Waldner MJ, Stolfi C, Sarra M, Fina D, Becker C, Neurath MF, Macdonald TT, Pallone F, Monteleone G, **Fantini MC**. Cancer Res. 2011 Dec 15;71(24):7423-32. doi: 10.1158/0008-5472.CAN-11-1895. Epub 2011 Oct 25.
46. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. Stolfi C, Rizzo A, Franzè E, Rotondi A, **Fantini MC**, Sarra M, Caruso R, Monteleone I, Sileri P, Franceschilli L, Caprioli F, Ferrero S, MacDonald TT, Pallone F, Monteleone G. J Exp Med. 2011 Oct 24;208(11):2279-90. doi: 10.1084/jem.20111106. Epub 2011 Oct 10.
47. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Stolfi C, Caruso R, Franzè E, Rizzo A, Rotondi A, Monteleone I, **Fantini MC**, Pallone F, Monteleone G. Mol Cancer Ther. 2011 Oct;10(10):1969-81. doi: 10.1158/1535-7163.MCT-11-0316. Epub 2011 Aug 4.
48. Regulation of homeostasis and inflammation in the intestine. MacDonald TT, Monteleone I, **Fantini MC**, Monteleone G. Gastroenterology. 2011 May;140(6):1768-75. doi: 10.1053/j.gastro.2011.02.047
49. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Monteleone G, **Fantini MC**, Onali S, Zorzi F, Sancesario G, Bernardini S, Calabrese E, Viti F, Monteleone I, Biancone L, Pallone F. Mol Ther. 2012 Apr;20(4):870-6. doi: 10.1038/mt.2011.290. Epub 2012 Jan 17.
50. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Zorzi F, Calabrese E, Monteleone I, **Fantini MC**, Onali S, Biancone L, Pallone F, Monteleone G. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.

51. Reprogramming the immune system in IBD. MacDonald TT, Vossenkaemper A, **Fantini MC**, Monteleone G. Dig Dis. 2012;30(4):392-5. doi: 10.1159/000338136. Epub 2012 Jul 12.
52. The impact of translational research on gastroenterology. Di Sabatino A, Moschetta A, Conte D, Tiribelli C; Translational Committee of the Italian Society of Gastroenterology, Caprioli FA, Fabris L, **Fantini MC**, Frulloni L, Monteleone G, Romano M, Sarnelli G, Baroni GS. Dig Liver Dis. 2014 Apr;46(4):293-4. doi: 10.1016/j.dld.2013.12.015. Epub 2014 Feb 5.
53. Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells. Rizzo A, De Mare V, Rocchi C, Stolfi C, Colantoni A, Neurath MF, Macdonald TT, Pallone F, Monteleone G, **Fantini MC**. Carcinogenesis. 2014 Jul;35(7):1536-46. doi: 10.1093/carcin/bgu027. Epub 2014 Jan 30.
54. A functional role for Smad7 in sustaining colon cancer cell growth and survival. Stolfi C, De Simone V, Colantoni A, Franzè E, Ribichini E, **Fantini MC**, Caruso R, Monteleone I, Sica GS, Sileri P, MacDonald TT, Pallone F, Monteleone G. Cell Death Dis. 2014 Feb 20;5:e1073. doi: 10.1038/cddis.2014.49.
55. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. De Simone V, Franzè E, Ronchetti G, Colantoni A, **Fantini MC**, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, Monteleone G, Stolfi C. Oncogene. 2015 Jul;34(27):3493-503. doi: 10.1038/onc.2014.286. Epub 2014 Sep 1.
56. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F. N Engl J Med. 2015 Mar 19;372(12):1104-13. doi: 10.1056/NEJMoa1407250.
57. Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis. De Simone V, Ronchetti G, Franzè E, Colantoni A, Ortenzi A, **Fantini MC**, Rizzo A, Sica GS, Sileri P, Rossi P, MacDonald TT, Pallone F, Monteleone G, Stolfi C. Oncotarget. 2015 Apr 30;6(12):9908-23.
58. Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation. Hasan M, Neumann B, Haupeltshofer S, Stahlke S, **Fantini MC**, Angstwurm K, Bogdahn U, Kleiter I. Immunol Cell Biol. 2015 Aug;93(7):662-72. doi: 10.1038/icb.2015.21. Epub 2015 Mar 31.
59. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group.
60. Dig Liver Dis. 2016 Apr;48(4):360-70. doi: 10.1016/j.dld.2015.12.016. Epub 2016 Jan 7.
61. CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide. Marafini I, Monteleone I, Dinallo V, Di Fusco D, De Simone V, Laudisi F, **Fantini MC**, Di Sabatino A, Pallone F, Monteleone G. J Crohns Colitis. 2017 May 1;11(5):603-609. doi: 10.1093/ecco-jcc/jjw191.
62. Smad7 knockdown activates protein kinase RNA-associated eIF2α pathway leading to colon cancer cell death. De Simone V, Bevivino G, Sedda S, Izzo R, Laudisi F, Dinallo V,

Franzè E, Colantoni A, Ortenzi A, Salvatori S, Rossi P, Sica GS, **Fantini MC**, Stolfi C, Monteleone G. Cell Death Dis. 2017 Mar 16;8(3):e2681. doi: 10.1038/cddis.2017.103.

63. Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down? **Fantini MC**, Monteleone G. Inflamm Bowel Dis. 2017 Oct;23(10):1682-1688. doi: 10.1097/MIB.0000000000001272. Review.
64. Reciprocal Regulation Between Smad7 and Sirt1 in the Gut. Sedda S, Franzè E, Bevivino G, Di Giovangiulio M, Rizzo A, Colantoni A, Ortenzi A, Grasso E, Giannelli M, Sica GS, **Fantini MC**, Monteleone G. Front Immunol. 2018 Aug 10;9:1854. doi: 10.3389/fimmu.2018.01854. eCollection 2018.
65. RORγt-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells. Rizzo A, Di Giovangiulio M, Stolfi C, Franzè E, Fehling HJ, Carsetti R, Giorda E, Colantoni A, Ortenzi A, Rugge M, Mescoli C, Monteleone G, **Fantini MC.** Cancer Immunol Res. 2018 Sep;6(9):1082-1092. doi: 10.1158/2326-6066.CIR-17-0698. Epub 2018 Jul 10.
66. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Viola A, Pugliese D, Renna S, Furfaro F, Caprioli F, D'Incà R, Bossa F, Mazza S, Costantino G, **Fantini MC**, Fiorino G, Alibrandi A, Orlando A, Armuzzi A, Fries W. Dig Liver Dis. 2018 Oct 28. pii: S1590-8658(18)31207-6. doi: 10.1016/j.dld.2018.10.013. [Epub ahead of print]
67. Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis. Tang Y, Reissig S, Glasmacher E, Regen T, Wanke F, Nikolaev A, Gerlach K, Popp V, Karram K, Fantini MC, Schattenberg JM, Galle PR, Neurath MF, Weigmann B, Kurschus FC, Hövelmeyer N, Waisman A. Gastroenterology. 2019 Feb;156(3):692-707.e7. doi: 10.1053/j.gastro.2018.10.023. Epub 2018 Oct 10.
68. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Viola A, Pugliese D, Renna S, Furfaro F, Caprioli F, D'Incà R, Bossa F, Mazza S, Costantino G, **Fantini MC**, Fiorino G, Alibrandi A, Orlando A, Armuzzi A, Fries W. Dig Liver Dis. 2019 Apr;51(4):510-515. doi: 10.1016/j.dld.2018.10.013. Epub 2018 Oct 28.
69. Heligmosomoides polygyrus bakeri Infection Decreases Smad7 Expression in Intestinal CD4+ T Cells, Which Allows TGF-β to Induce IL-10-Producing Regulatory T Cells That Block Colitis. Hang L, Kumar S, Blum AM, Urban JF Jr, **Fantini MC**, Weinstock JV. J Immunol. 2019 Apr 15;202(8):2473-2481. doi: 10.4049/jimmunol.1801392. Epub 2019 Mar 8.
70. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, **Fantini MC**, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients' association representatives; IG-IBD members. Dig Liver Dis. 2019 May;51(5):632-639. doi: 10.1016/j.dld.2019.02.004. Epub 2019 Feb 19. Review.
71. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, **Fantini MC**; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Inflamm Bowel Dis. 2019 Oct 18;25(11):1805-1812. doi: 10.1093/ibd/izz057

72. The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective .Onali S, Favale A, **Fantini MC**. Cells. 2019 Apr 11;8(4). pii: E344. doi: 10.3390/cells8040344. Review.
73. Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis. Di Giovangiulio M, Rizzo A, Franzè E, Caprioli F, Facciotti F, Onali S, Favale A, Stolfi C, Fehling HJ, Monteleone G, **Fantini MC**. Front Immunol. 2019 Sep 11;10:2158. doi: 10.3389/fimmu.2019.02158. eCollection 2019.
74. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history. Magrì S, Paduano D, Chicco F, Cingolani A, Farris C, Delogu G, Tumbarello F, Lai M, Melis A, Casula L, **Fantini MC**, Usai P. World J Gastroenterol. 2019 Oct 7;25(37):5676-5686. doi: 10.3748/wjg.v25.i37.5676.
75. Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. Lenti MV, Armuzzi A, Castiglione F, **Fantini MC**, Fiorino G, Orlando A, Pugliese D, Rizzello F, Vecchi M, Di Sabatino A; IG-IBD. Dig Liver Dis. 2020 Jan;52(1):44-50. doi: 10.1016/j.dld.2019.09.019. Epub 2019 Oct 21.
76. Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis.
77. Haupeltshofer S, Leichsenring T, Berg S, Pedreiturria X, Joachim SC, Tischoff I, Otte JM, Bopp T, **Fantini MC**, Esser C, Willbold D, Gold R, Faissner S, Kleiter I. Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25860-25869. doi: 10.1073/pnas.1905955116. Epub 2019 Dec 3.
78. Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease. Zorzi F, Ghosh S, Chiaramonte C, Lolli E, Ventura M, Onali S, De Cristofaro E, **Fantini MC**, Biancone L, Monteleone G, Calabrese E. Clin Gastroenterol Hepatol. 2019 Dec 20. pii: S1542-3565(19)31244-3. doi: 10.1016/j.cgh.2019.10.042. [Epub ahead of print]
79. Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases. Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, **Fantini MC**, Vecchi M, Geginat J, Caprioli F. J Crohns Colitis. 2020 Feb 26. pii: jjaa035. doi: 10.1093/ecco-jcc/jjaa035. [Epub ahead of print]
80. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, **Fantini MC**, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Gut. 2020 Jul;69(7):1213-1217. doi: 10.1136/gutjnl-2020-321411. Epub 2020 Apr 30. PMID: 32354990
81. The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation. Amoroso C, Perillo F, Strati F, **Fantini MC**, Caprioli F, Facciotti F. Cells. 2020 May 16;9(5):1234. doi: 10.3390/cells9051234.
82. The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation. Amoroso C, Perillo F, Strati F, **Fantini MC**, Caprioli F, Facciotti F. Cells. 2020 May 16;9(5):1234. doi: 10.3390/cells9051234.

83. Multidimensional Impact of Mediterranean Diet on IBD Patients. Chicco F, Magrì S, Cingolani A, Paduano D, Pesenti M, Zara F, Tumbarello F, Urru E, Melis A, Casula L, Fantini MC, UsDual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A, Ribaldone DG, Buda A, Bezzio C, Fiorino G, **Fantini MC**, Scaldaferri F, Guidi L, Danese S, Gasbarrini A, Orlando A, Armuzzi A. J Crohns Colitis. 2020 Jul 17:jjaa149. doi: 10.1093/ecco-jcc/jjaa149. Online ahead of print. PMID: 32674156ai P. Inflamm Bowel Dis. 2021 Jan 1;27(1):1-9. doi: 10.1093/ibd/izaa097.
84. Tumor Infiltrating Regulatory T Cells in Sporadic and Colitis-Associated Colorectal Cancer: The Red Little Riding Hood and the Wolf. **Fantini MC**, Favale A, Onali S, Facciotti F. Int J Mol Sci. 2020 Sep 14;21(18):6744. doi: 10.3390/ijms21186744.
85. Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. **Fantini MC**, Biancone L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Guglielmi FW, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Di Ruscio M, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, Saibeni S, Fiorino G. Inflamm Bowel Dis. 2020 Oct 23;26(11):e134-e136. doi: 10.1093/ibd/izaa254.
86. Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. Saibeni S, Scucchi L, Dragoni G, Bezzio C, Miranda A, Ribaldone DG, Bertani A, Bossa F, Allocca M, Buda A, Mocci G, Soriano A, Mazzuoli S, Bertani L, Baccini F, Loddo E, Privitera AC, Sartini A, Viscido A, Grossi L, Casini V, Gerardi V, Ascolani M, Ruscio MD, Casella G, Savarino E, Stradella D, Pumpo R, Cortelezzi CC, Daperno M, Ciardo V, Nardone OM, Caprioli F, Vitale G, Cappello M, Comberlato M, Alvisi P, Festa S, Campigotto M, Bodini G, Balestrieri P, Viola A, Pugliese D, Armuzzi A, **Fantini MC**, Fiorino G; IG-IBD (Italian Group for the study of Inflammatory Bowel Disease). United European Gastroenterol J. 2020 Dec;8(10):1228-1235. doi: 10.1177/2050640620964132. Epub 2020 Oct 18.
87. Seroprevalence of SARS-CoV2 in IBD patients treated with biological therapy. Berte' R, Mazza S, Stefanucci MR, Noviello D, Costa S, Ciafardini C, Mileti E, Mapelli M, Pasqualato S, Pinto S, Favale A, Vecchi M, Neurath MF, Atreya R, **Fantini MC**, Facciotti F, Caprioli F. J Crohns Colitis. 2020 Nov 19:jjaa237. doi: 10.1093/ecco-jcc/jjaa237. Online ahead of print.
88. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies. **Fantini MC**, Guadagni I.Dig Liver Dis. 2021 Feb 1:S1590-8658(21)00018-9. doi: 10.1016/j.dld.2021.01.012. Online ahead of print.
89. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, **Fantini MC**, Biancone L, Calabrese E, Di Grazia A, Monteleone I, Lenti MV, Di Sabatino A, Monteleone G. BioDrugs. 2021 May;35(3):325-336. doi: 10.1007/s40259-021-00482-x. Epub 2021 Apr 19.
90. Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic.

Pinto S, Loddo E, Paba S, Favale A, Chicco F, Onali S, Usai P, **Fantini MC**. J Patient Rep Outcomes. 2021 Jun 24;5(1):48. doi: 10.1186/s41687-021-00323-z.

91. Immune system and gut microbiota senescence in elderly IBD patients. **Fantini MC**, Onali S, Gasbarrini A, Lopetuso LR. Minerva Gastroenterol (Torino). 2021 Jul 19. doi: 10.23736/S2724-5985.21.02934-X. Online ahead of print.
92. Quercetin and its derivates as antiviral potentials: A comprehensive review. Di Petrillo A, Orrù G, Fais A, **Fantini MC**. Phytother Res. 2021 Oct 28. doi: 10.1002/ptr.7309. Online ahead of print.
93. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, **Fantini MC,** Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Dig Liver Dis. 2022 Apr;54(4):440-451. doi: 10.1016/j.dld.2022.01.127. Epub 2022 Feb 17.
94. IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes. Burrello C, Strati F, Lattanzi G, Diaz-Basabe A, Mileti E, Giuffrè MR, Lopez G, Cribiù FM, Trombetta E, Kallikourdis M, Cremonesi M, Conforti F, Botti F, Porretti L, Rescigno M, Vecchi M, **Fantini MC**, Caprioli F, Facciotti F. J Crohns Colitis. 2022 Sep 8;16(9):1461-1474. doi: 10.1093/ecco-jcc/jjac049.
95. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors. Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, Imperatore N, Fiorino G, Cappello M, Viola A, Principi MB, Bezzio C, Aratari A, Carparelli S, Mazzuoli S, Manguso F, Grossi L, Bodini G, Ribaldone D, Mocci G, Miranda A, Minerba L, Favale A, Grova M, Scucchi L, Segato S, Fries W, Castiglione F, Armuzzi A, **Fantini MC**; IG-IBD. Am J Gastroenterol. 2022 Aug 1;117(8):1279-1287. doi: 10.14309/ajg.0000000000001773. Epub 2022 Apr 13.
96. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study. Macaluso FS, Principi M, Facciotti F, Contaldo A, Todeschini A, Saibeni S, Bezzio C, Castiglione F, Nardone OM, Spagnuolo R, **Fantini MC**, Riguccio G, Caprioli F, Viganò C, Felice C, Fiorino G, Correale C, Bodini G, Milla M, Scardino G, Vernero M, Desideri F, Mannino M, Rizzo G, Orlando A; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2023 Feb;55(2):154-159. doi: 10.1016/j.dld.2022.08.027. Epub 2022 Aug 29.
97. Advanced imaging and Crohn's disease: An overview of clinical application and the added value of artificial intelligence. Grassi G, Laino ME, **Fantini MC**, Argiolas GM, Cherchi MV, Nicola R, Gerosa C, Cerrone G, Mannelli L, Balestrieri A, Suri JS, Carriero A, Saba L. Eur J Radiol. 2022 Dec;157:110551. doi: 10.1016/j.ejrad.2022.110551. Epub 2022 Oct 3.
98. Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study. Magrì S, Demurtas M, Onidi MF, Picchio M, Elisei W, Marzo M, Miculan F, Manca R, Dore MP, Quarta Colosso BM, Cicu A, Cugia L, Carta M, Binaghi L, Usai P, Lai M, Chicco F, **Fantini MC**, Armuzzi A, Mocci G. World J Clin Cases. 2022 Oct 26;10(30):10921-10930. doi: 10.12998/wjcc.v10.i30.10921.
99. Diagnostic delay in adult coeliac disease: An Italian multicentre study.
100. Lenti MV, Aronico N, Bianchi PI, D'Agate CC, Neri M, Volta U, Mumolo MG, Astegiano M, Calabrò AS, Zingone F, Latella G, Di Sario A, Carroccio A, Ciacci C, Luzza F, Bagnato C,

Fantini MC, Elli L, Cammarota G, Gasbarrini A, Portincasa P, Latorre MA, Petrucci C, Quatraccioni C, Iannelli C, Vecchione N, Rossi CM, Broglio G, Ianiro G, Marsilio I, Bibbò S, Marinoni B, Tomaselli D, Abenavoli L, Pilia R, Santacroce G, Lynch E, Carrieri A, Mansueto P, Gabba M, Alunno G, Rossi C, Onnis F, Efthymakis K, Cesaro N, Vernero M, Baiano Svizzero F, Semeraro FP, Silano M, Vanoli A, Klersy C, Corazza GR, Di Sabatino A. Dig Liver Dis. 2023 Jun;55(6):743-750. doi: 10.1016/j.dld.2022.11.021. Epub 2022 Dec 23.

101. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology. Macaluso FS, Papi C, Orlando A, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, **Fantini MC,** Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD); Working panel; Review panel. Dig Liver Dis. 2023 Apr;55(4):442-453. doi: 10.1016/j.dld.2023.01.155. Epub 2023 Feb 13.
102. Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study. Dragoni G, Castiglione F, Bezzio C, Pugliese D, Spagnuolo R, Viola A, Cocomazzi F, Aratari A, Savarino EV, Balestrieri P, Onali S, Viganò C, Ribaldone DG, Innocenti T, Testa A, Saibeni S, Privitera G, Milla M, Armuzzi A, **Fantini MC**, Fiorino G. United European Gastroenterol J. 2023 Apr;11(3):271-281. doi: 10.1002/ueg2.12367. Epub 2023 Mar 21.
103. Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease. Lenti MV, Scribano ML, Biancone L, Ciccocioppo R, Pugliese D, Pastorelli L, Fiorino G, Savarino E, Caprioli FA, Ardizzone S, Fantini MC, Tontini GE, Orlando A, Sampietro GM, Sturniolo GC, Monteleone G, Vecchi M, Kohn A, Daperno M, D'Incà R, Corazza GR, Di Sabatino A. Front Med (Lausanne). 2023 Apr 11;10:1031998. doi: 10.3389/fmed.2023.1031998. eCollection 2023.
104. Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab. Carpineti C, Mugheddu C, Cadoni M, Anedda J, Atzori L, Fantini MC, Onali S. Inflamm Bowel Dis. 2023 Sep 1;29(9):1512-1514. doi: 10.1093/ibd/izad107.
105. Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review. Fantini MC, Loddo E, Petrillo AD, Onali S. Dig Liver Dis. 2024 Jan;56(1):1-6. doi: 10.1016/j.dld.2023.05.035. Epub 2023 Jun 15.
106. Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study. Macaluso FS, Principi M, Facciotti F, Contaldo A, Todeschini A, Saibeni S, Bezzio C, Castiglione F, Nardone OM, Spagnuolo R, Fantini MC, Riguccio G, Conforti S, Caprioli F, Viganò C, Felice C, Fiorino G, Correale C, Bodini G, Milla M, Scardino G, Vernero M, Desideri F, Bossa F, Guerra M, Ventimiglia M, Casà A, Rizzo G, Orlando A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Inflamm Bowel Dis. 2023 Jun 30:izad118. doi: 10.1093/ibd/izad118.
107. GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease. Di Petrillo A, Kumar A, Onali S, Favale A, Fantini MC. Inflamm Bowel Dis. 2023 Dec 5;29(12):1981-1989. doi: 10.1093/ibd/izad161.
108. Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations. Schreiber S, Danese S, Dignass A, Domènech E, Fantini MC, Ferrante M, Halfvarson J, Hart A, Magro

F, Lees CW, Leone S, Pierik MJ, Peters M, Field P, Fishpool H, Peyrin-Biroulet L. J Crohns Colitis. 2024 Jan 27;18(1):91-105. doi: 10.1093/ecco-jcc/jjad130.

109. Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus. Ardizzone S, Armuzzi A, Caprioli F, Castiglione F, Danese S, Daperno M, Fantini MC, Fries W, Principi MB, Savarino E, Gionchetti P. Dig Liver Dis. 2024 Jan;56(1):98-105. doi: 10.1016/j.dld.2023.09.003. Epub 2023 Sep 21.
110. Inhibitory Effect of Quercetin on Oxidative Endogen Enzymes: A Focus on Putative Binding Modes. Olla S, Siguri C, Fais A, Era B, Fantini MC, Di Petrillo A. Int J Mol Sci. 2023 Oct 20;24(20):15391. doi: 10.3390/ijms242015391.
111. Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus. Fantini MC, Fiorino G, Colli A, Laharie D, Armuzzi A, Caprioli FA, Gisbert JP, Kirchgesner J, Macaluso FS, Magro F, Ghosh S; PRACTICE-IBD study group. J Crohns Colitis. 2024 Feb 17:jjae026. doi: 10.1093/ecco-jcc/jjae026. Online ahead of print.
112. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus. Macaluso FS, Caprioli F, Benedan L, Bezzio C, Caporali R, Cauli A, Chimenti MS, Ciccia F, D'Angelo S, Fantini MC, Festa S, Iannone F, Lubrano E, Mariani P, Papi C, Provenzano G, Pugliese D, Rispo A, Saibeni S, Salvarani C, Variola A, Zenga M, Armuzzi A, Orlando A, Gerli R. Autoimmun Rev. 2024 Mar 22;23(5):103533. doi: 10.1016/j.autrev.2024.103533. Online ahead of print.

Date: 18th March 2025

Massimo C Fantini